Lessons from GSK in China – Internal Controls, Auditing and Monitoring

Published date25 September 2014
Law FirmThomas Fox
Subject MatterAudits,Chief Compliance Officers,China,Compliance,Corporate Fines,Corporate Integrity Agreement,Enforcement Actions,FCPA,GlaxoSmithKline,Healthcare,Hospitals,Internal Audit Functions,Internal Controls,Pharmaceutical Industry,Physicians

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT